Compare Regeneron Pharmaceuticals Inc (REGN) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Tencent Music Entertainment Group - ADR — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B), while Tencent Music Entertainment Group - ADR trades at $7.94 (market cap $13.50B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 6.2× Tencent Music Entertainment Group - ADR's market cap, and Tencent Music Entertainment Group - ADR pays the higher dividend (2.98%). Which is the better fit depends on your goals.
| REGN | TME | |
|---|---|---|
Market Cap | $83.43B | $13.50B |
Sector | Health | Media |
52-Week High | $852.03 | $26.36 |
52-Week Low | $555.51 | $7.89 |
Enterprise Value | $78.14B | $11.44B |
Dividend Yield | 0.46% | 2.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Tencent Music Entertainment (TME) trades at $8.06, down 2.42% on the day, with a bearish technical signal from moving averages but oversold RSI levels. The company reported strong Q2 2026 earnings with a beat on EPS and revenue growth of 6% year-over-year, though recent news highlights a $1 billion notes offering and mixed analyst sentiment amid competitive pressures.
The outlook is balanced: TME's low P/E of 9.46 and net income margin of 26.28% offer value, but slowing growth and rising debt pose risks. Analysts have a consensus price target of $12.15, suggesting upside, but investors should weigh competitive threats from rivals like ByteDance's Soda Music against the company's fan economy transition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →
